Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy
Among breast cancers, triple-negative breast cancer (TNBC) has been recognized as the most aggressive type with a poor prognosis and low survival rate. Targeted therapy for TNBC is challenging because it lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor rece...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-08-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/11/8/830 |
| _version_ | 1827135140746231808 |
|---|---|
| author | Md Abdus Subhan Vladimir P. Torchilin |
| author_facet | Md Abdus Subhan Vladimir P. Torchilin |
| author_sort | Md Abdus Subhan |
| collection | DOAJ |
| description | Among breast cancers, triple-negative breast cancer (TNBC) has been recognized as the most aggressive type with a poor prognosis and low survival rate. Targeted therapy for TNBC is challenging because it lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Chemotherapy, radiation therapy, and surgery are the common therapies for TNBC. Although TNBC is prone to chemotherapy, drug resistance and recurrence are commonly associated with treatment failure. Combination therapy approaches using chemotherapy, mAbs, ADC, and antibody–siRNA conjugates may be effective in TNBC. Recent advances with siRNA-based therapy approaches are promising for TNBC therapy with better prognosis and reduced mortality. This review discusses advances in nanomaterial- and nanobiomaterial-based siRNA delivery platforms for TNBC therapy exploring targeted therapy approaches for major genes, proteins, and TFs upregulated in TNBC tumors, which engage in molecular pathways associated with low TNBC prognosis. Bioengineered siRNA drugs targeting one or several genes simultaneously can downregulate desired genes, significantly reducing disease progression. |
| first_indexed | 2025-03-20T17:30:56Z |
| format | Article |
| id | doaj.art-8435a3aedc014d3783f384e946b036f8 |
| institution | Directory Open Access Journal |
| issn | 2306-5354 |
| language | English |
| last_indexed | 2025-03-20T17:30:56Z |
| publishDate | 2024-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj.art-8435a3aedc014d3783f384e946b036f82024-08-28T14:06:44ZengMDPI AGBioengineering2306-53542024-08-0111883010.3390/bioengineering11080830Advances in siRNA Drug Delivery Strategies for Targeted TNBC TherapyMd Abdus Subhan0Vladimir P. Torchilin1Division of Nephrology, University of Rochester, 601 Elmwood Ave, Rochester, NY 14642, USACenter for Pharmaceutical Biotechnology and Nanomedicine, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USAAmong breast cancers, triple-negative breast cancer (TNBC) has been recognized as the most aggressive type with a poor prognosis and low survival rate. Targeted therapy for TNBC is challenging because it lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Chemotherapy, radiation therapy, and surgery are the common therapies for TNBC. Although TNBC is prone to chemotherapy, drug resistance and recurrence are commonly associated with treatment failure. Combination therapy approaches using chemotherapy, mAbs, ADC, and antibody–siRNA conjugates may be effective in TNBC. Recent advances with siRNA-based therapy approaches are promising for TNBC therapy with better prognosis and reduced mortality. This review discusses advances in nanomaterial- and nanobiomaterial-based siRNA delivery platforms for TNBC therapy exploring targeted therapy approaches for major genes, proteins, and TFs upregulated in TNBC tumors, which engage in molecular pathways associated with low TNBC prognosis. Bioengineered siRNA drugs targeting one or several genes simultaneously can downregulate desired genes, significantly reducing disease progression.https://www.mdpi.com/2306-5354/11/8/830triple-negative breast cancersiRNAbiomaterialsnanomaterialstargeted therapy |
| spellingShingle | Md Abdus Subhan Vladimir P. Torchilin Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy Bioengineering triple-negative breast cancer siRNA biomaterials nanomaterials targeted therapy |
| title | Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy |
| title_full | Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy |
| title_fullStr | Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy |
| title_full_unstemmed | Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy |
| title_short | Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy |
| title_sort | advances in sirna drug delivery strategies for targeted tnbc therapy |
| topic | triple-negative breast cancer siRNA biomaterials nanomaterials targeted therapy |
| url | https://www.mdpi.com/2306-5354/11/8/830 |
| work_keys_str_mv | AT mdabdussubhan advancesinsirnadrugdeliverystrategiesfortargetedtnbctherapy AT vladimirptorchilin advancesinsirnadrugdeliverystrategiesfortargetedtnbctherapy |